Background/Aim: The current standard of care for first-line treatment of locally advanced or metastatic urothelial carcinoma (UC) is platinum-based combination chemotherapy. Recently, immune checkpoint inhibitors have been reported to be effective for UC. Knowing whether immunotherapy or chemotherapy is suitable as first-line treatment is beneficial for patients. A retrospective study was conducted on the clinical outcomes of Japanese patients who received three or more courses of first-line chemotherapy for metastatic UC to assess the outcome of conventional treatments in real clinical situation. Patients and Methods: Patients who received first-line chemotherapy between August 2009 and December 2019 were included. Progression-free survival (PFS) and overall survival (OS) were assessed. Results: The median PFS and OS were 7.1 and 27.1 months, respectively, for patients with no disease progression at the end of three courses. Of 28 patients, 25 (89.3%) received second-line drug therapy and 10 (35.7%) received focal therapy for disease control. Patients with focal therapy had significantly longer OS than those without focal therapy (p=0.019, log-rank test). Conclusion: OS of metastatic UC at our Institution is relatively long, suggesting that aggressive second-line drug therapy and focal therapy may have contributed to such result. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: The current standard of care for first-line treatment of locally advanced or metastatic urothelial carcinoma (UC) is platinum-based combination chemotherapy. Recently, immune checkpoint inhibitors have been reported to be effective for UC. Knowing whether immunotherapy or chemotherapy is suitable as first-line treatment is beneficial for patients. A retrospective study was conducted on the clinical outcomes of Japanese patients who received three or more courses of first-line chemotherapy for metastatic UC to assess the outcome of conventional treatments in real clinical situation. Patients and Methods: Patients who received first-line chemotherapy between August 2009 and December 2019 were included. Progression-free survival (PFS) and overall survival (OS) were assessed. Results: The median PFS and OS were 7.1 and 27.1 months, respectively, for patients with no disease progression at the end of three courses. Of 28 patients, 25 (89.3%) received second-line drug therapy and 10 (35.7%) received focal therapy for disease control. Patients with focal therapy had significantly longer OS than those without focal therapy (p=0.019, log-rank test). Conclusion: OS of metastatic UC at our Institution is relatively long, suggesting that aggressive second-line drug therapy and focal therapy may have contributed to such result. Copyright 2021, International Institute of Anticancer Research.
Authors: Keiichiro Mori; Benjamin Pradere; Marco Moschini; Hadi Mostafaei; Ekaterina Laukhtina; Victor M Schuettfort; Reza Sari Motlagh; Francesco Soria; Jeremy Y C Teoh; Shin Egawa; Thomas Powles; Shahrokh F Shariat Journal: Eur J Cancer Date: 2021-05-04 Impact factor: 9.162
Authors: Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin Journal: Lancet Date: 2016-12-08 Impact factor: 79.321
Authors: Thomas Powles; Se Hoon Park; Eric Voog; Claudia Caserta; Begoña P Valderrama; Howard Gurney; Haralabos Kalofonos; Siniša Radulović; Wim Demey; Anders Ullén; Yohann Loriot; Srikala S Sridhar; Norihiko Tsuchiya; Evgeny Kopyltsov; Cora N Sternberg; Joaquim Bellmunt; Jeanny B Aragon-Ching; Daniel P Petrylak; Robert Laliberte; Jing Wang; Bo Huang; Craig Davis; Camilla Fowst; Nuno Costa; John A Blake-Haskins; Alessandra di Pietro; Petros Grivas Journal: N Engl J Med Date: 2020-09-18 Impact factor: 91.245
Authors: Jacqueline Vuky; Arjun V Balar; Daniel Castellano; Peter H O'Donnell; Petros Grivas; Joaquim Bellmunt; Thomas Powles; Dean Bajorin; Noah M Hahn; Mary J Savage; Xiao Fang; James Luke Godwin; Tara L Frenkl; Blanca Homet Moreno; Ronald de Wit; Elizabeth R Plimack Journal: J Clin Oncol Date: 2020-06-17 Impact factor: 44.544